Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2164 Target Snapshot

Serine/threonine-protein phosphatase PP1-alpha catalytic subunit · SINGLE PROTEIN · Homo sapiens

134Compounds
14Assays
0Approved Drugs
130.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt P62136. Use UniProt P62136 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P62136 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein phosphatase PP1-alpha catalytic subunit as ChEMBL target CHEMBL2164, mapped to UniProt P62136. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein phosphatase PP1-alpha catalytic subunit
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2164
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P62136
Serine/threonine-protein phosphatase PP1-alpha catalytic subunit
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein phosphatase PP1-alpha catalytic subunit is the right protein anchor across sources, using UniProt P62136 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein phosphatase PP1-alpha catalytic subunit
UniProt AccessionP62136
Component TypeProtein
Sequence Length330 aa

Serine/threonine-protein phosphatase PP1-alpha catalytic subunit

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Serine/threonine-protein phosphatase PP1-alpha catalytic subunit, mapped to UniProt P62136. Sequence length is 330 aa.

Mapped IDP62136
Review nameSerine/threonine-protein phosphatase PP1-alpha catalytic subunit
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

1
Phase II
Assay Mix

Activity Type Distribution

IC50129.0
KI1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1344034 6.64 IC50 227.35 Preclinical
CHEMBL299846 6.57 IC50 271.6 Preclinical
CHEMBL1519313 5.71 IC50 1971.0 Preclinical
CHEMBL1530097 5.63 IC50 2363.0 Preclinical
CHEMBL1503729 5.61 IC50 2477.0 Preclinical
CHEMBL1533230 5.61 IC50 2463.0 Preclinical
CHEMBL567967 5.57 IC50 2667.0 Preclinical
CHEMBL1329288 5.55 IC50 2846.0 Preclinical
CHEMBL8327 5.55 IC50 2832.0 Preclinical
CHEMBL1455825 5.44 IC50 3632.0 Preclinical
Distribution

pChEMBL Value Distribution

55
5.0
7
5.5
0
6.0
2
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

14
Total Assays
91
Tested Compounds
1
Assay Types
Binding — 14 assays, 91 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 13 91 5.0
cell-based format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine